The intranasal delivery system bypasses the digestive tract, allowing the medication to remain effective regardless of food intake. Clinical data indicates that the spray reaches peak concentration levels in a median of 10 minutes, utilizing only a quarter of the typical oral dose. This rapid absorption profile remains consistent even in men aged 65 and older, who often face slower metabolic processing with conventional tablets.
Lee Rodne, Executive Chairman of LTR Pharma, noted that the product aims to remove the logistical hurdles of planning around meals. Dr. Amy Pearlman, a urologist on the company's scientific advisory board, emphasized that the shift toward nasal administration prioritizes spontaneity and discretion for patients. While the medication is now available nationwide, it is dispensed as a compounded product through the Mavrox telemedicine platform. Patients must complete a health assessment for review by a licensed provider, who then directs fulfillment through Strive Pharmacy.
:max_bytes(150000):strip_icc()/Mucinex-Sinus-Max-Nasal-Spray-Decongestant-07c823dce5b04e8a9c82a91074ebcc05.jpg)



Comments (0)
No comments yet. Be the first!